These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32481593)

  • 1. Heparin Blocks the Inhibition of Tissue Kallikrein 1 by Kallistatin through Electrostatic Repulsion.
    Ma L; Wu J; Zheng Y; Shu Z; Wei Z; Sun Y; Carrell RW; Zhou A
    Biomolecules; 2020 May; 10(6):. PubMed ID: 32481593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein.
    Chen VC; Chao L; Chao J
    J Biol Chem; 2000 Dec; 275(51):40371-7. PubMed ID: 10991942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein.
    Chen VC; Chao L; Chao J
    J Biol Chem; 2000 Dec; 275(49):38457-66. PubMed ID: 10993887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin.
    Leu CH; Yang ML; Chung NH; Huang YJ; Su YC; Chen YC; Lin CC; Shieh GS; Chang MY; Wang SW; Chang Y; Chao J; Chao L; Wu CL; Shiau AL
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5619-30. PubMed ID: 26149981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a major heparin-binding site in kallistatin.
    Chen VC; Chao L; Pimenta DC; Bledsoe G; Juliano L; Chao J
    J Biol Chem; 2001 Jan; 276(2):1276-84. PubMed ID: 11016932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence.
    Zhou GX; Chao L; Chao J
    J Biol Chem; 1992 Dec; 267(36):25873-80. PubMed ID: 1334488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural elements of kallistatin required for inhibition of angiogenesis.
    Miao RQ; Chen V; Chao L; Chao J
    Am J Physiol Cell Physiol; 2003 Jun; 284(6):C1604-13. PubMed ID: 12734113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis.
    Chen VC; Chao L; Chao J
    Biochim Biophys Acta; 2000 Jun; 1479(1-2):237-46. PubMed ID: 10862973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystallization and crystallographic studies of kallistatin.
    Lin F; Zhou A; Wei Z
    Acta Crystallogr F Struct Biol Commun; 2015 Sep; 71(Pt 9):1135-8. PubMed ID: 26323298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A unique serpin P1' glutamate and a conserved β-sheet C arginine are key residues for activity, protease recognition and stability of serpinA12 (vaspin).
    Ulbricht D; Pippel J; Schultz S; Meier R; Sträter N; Heiker JT
    Biochem J; 2015 Sep; 470(3):357-67. PubMed ID: 26199422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemistry, regulation and potential function of kallistatin.
    Chao J; Chao L
    Biol Chem Hoppe Seyler; 1995 Dec; 376(12):705-13. PubMed ID: 9072045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of S'1 and S'2 subsites of human tissue kallikrein using the reactive-centre loop of kallistatin: the importance of P'1 and P'2 positions in design of inhibitors.
    Pimenta DC; Fogaça SE; Melo RL; Juliano L; Juliano MA
    Biochem J; 2003 May; 371(Pt 3):1021-5. PubMed ID: 12578561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue kallikrein inhibitors in mammals.
    Chao J; Chai KX; Chao L
    Immunopharmacology; 1996 May; 32(1-3):67-72. PubMed ID: 8796269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin.
    Bläckberg M; Berling R; Ohlsson K
    Pancreas; 1999 Nov; 19(4):325-34. PubMed ID: 10547191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.
    Stadnicki A; Mazurek U; Plewka D; Wilczok T
    Int Immunopharmacol; 2003 Jul; 3(7):939-44. PubMed ID: 12810351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes.
    Myles T; Church FC; Whinna HC; Monard D; Stone SR
    J Biol Chem; 1998 Nov; 273(47):31203-8. PubMed ID: 9813026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling.
    Chao J; Miao RQ; Chen V; Chen LM; Chao L
    Biol Chem; 2001 Jan; 382(1):15-21. PubMed ID: 11258665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases.
    Sexton DJ; Chen T; Martik D; Kuzmic P; Kuang G; Chen J; Nixon AE; Zuraw BL; Forteza RM; Abraham WM; Wood CR
    Biochem J; 2009 Aug; 422(2):383-92. PubMed ID: 19527222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular localization of kallistatin and tissue kallikrein in human pancreas and salivary glands.
    Wolf WC; Harley RA; Sluce D; Chao L; Chao J
    Histochem Cell Biol; 1998 Nov; 110(5):477-84. PubMed ID: 9826127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localization and expression of tissue kallikrein and kallistatin in human blood vessels.
    Wolf WC; Harley RA; Sluce D; Chao L; Chao J
    J Histochem Cytochem; 1999 Feb; 47(2):221-8. PubMed ID: 9889257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.